

Notification to our patients and the public

By CCMB Public Affairs Communications

Mon Aug 20 11:57:00 CDT 2018

Under-dosing of intravenous anti-cancer treatment

CancerCare Manitoba's foremost concern is for all of our patients' physical and emotional well-being. Unfortunately, we recently learned about potential under-dosing of cancer patients and we would like to extend our sincere apologies for this issue. CancerCare Manitoba chose not to connect with patients immediately as the risk to patients is low.

CancerCare Manitoba would like to be clear that this under-dosing does not affect everyone receiving chemotherapy. We have thoroughly investigated this issue and determined that it affects 175 patients, treated with three specific anti-cancer drugs: pembrolizumab, nivolumab and ipilimumab.

CancerCare Manitoba has taken the following steps:

- Affected patients will receive a phone call this week with an explanation around the issue
- A different physical drug delivery system has been put in place so that this is no longer an issue in delivering the above three intravenous anti-cancer drugs
- The Quality Patient and Safety team at CancerCare Manitoba will continue to review our processes and implement recommendations that will come out of the review

Patients can address any questions or concerns at their usual appointments or by phoning their oncologist and their clinical care team.

Our CCMB Patient Representative Office is also available at CCMBpatrep@cancercare.mb.ca (mailto:CCMBpatrep@cancercare.mb.ca), 204-787-2065 or toll free at 1-866-561-1026.

CancerCare Manitoba apologizes for any anxiety this may have caused our patients and their families.